https://www.yiliao.com/index.php?action=history&feed=atom&title=%E9%80%8F%E6%98%8E%E7%BB%86%E8%83%9E%E7%99%8C
透明细胞癌 - 版本历史
2026-04-19T17:45:13Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=%E9%80%8F%E6%98%8E%E7%BB%86%E8%83%9E%E7%99%8C&diff=313466&oldid=prev
223.160.138.166：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-07T05:00:26Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[透明细胞癌]]([[Clear Cell Carcinoma, CCC]])</strong>是一类以胞浆内富含糖原和脂质、在常规[[H&E]]染色下呈现“透明状”为特征的恶性上皮性肿瘤。在2026年的肿瘤分子分类学中，[[CCC]]并非单一疾病，而是发生于多器官的异质性群体，最常见于<strong>[[肾脏]]([[ccRCC]])</strong>、<strong>[[卵巢]]</strong>及<strong>[[子宫内膜]]</strong>。其核心分子特征常涉及<strong>[[染色体3p]]</strong>缺失导致的<strong>[[VHL]]</strong>抑癌基因失活，或[[ARID1A]]等染色质重塑基因的突变。由于其独特的代谢重编程（如典型的**[[华堡效应]]**），[[CCC]]对传统放化疗往往表现出不同程度的抵抗，目前的治疗范式已全面转向<strong>[[抗血管生成]]</strong>联合<strong>[[免疫检查点抑制]]</strong>。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">透明细胞癌</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Clear Cell Carcinoma·点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 15px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">Histology: Clear Cytoplasm due to Glycogen/Lipid loss</div><br />
</div><br />
<br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">主要驱动基因：[[VHL]]•[[ARID1A]]</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">[[Entrez]]ID</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">7417([[VHL]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]]编号</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">12687</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">P40337</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">ICD-11编码</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">2C94.0/2C70.Y</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">染色体异常</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[3p25.3]]缺失</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">关键标志物</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">CAIX•HNF1B•PAX8</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">2026热点</th><br />
<td style="padding: 12px; color: #b91c1c;">HIF-2&alpha; 拮抗序贯</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：从伪缺氧状态到代谢重塑</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[透明细胞癌]]的致癌逻辑在2026年被解析为高度集中的信号级联异常：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>VHL 失活与伪缺氧：</strong> 以肾[[ccRCC]]为例，<strong>[[VHL]]</strong>蛋白缺失导致其无法泛素化降解<strong>[[缺氧诱导因子]]([[HIF-&alpha;]])</strong>。HIF在细胞核内持续积聚，诱发“**[[伪缺氧]]**”反应，即便在氧气充足的环境下也激活血管新生基因（[[VEGF]]）和葡萄糖转运基因（[[GLUT1]]）。</li><br />
<li style="margin-bottom: 12px;"><strong>ARID1A 与染色质失调：</strong> 在卵巢透明细胞癌中，超过50%的病例存在<strong>[[ARID1A]]</strong>突变。这种[[SWI/SNF]]复合体成员的缺失导致全基因组层面的染色质开放性改变，协同激活[[PI3K/AKT/mTOR]]通路。</li><br />
<li style="margin-bottom: 12px;"><strong>代谢表型重构：</strong> [[CCC]]细胞表现出极端的[[华堡效应]]，高度依赖糖酵解。2026年代谢组学证实，这种代谢特征不仅为了供能，更通过积累[[1-磷酸葡萄糖]]等中间体构建了抗氧化的胞内稳态。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026器官特异性 CCC 临床特征对比</h2><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">器官亚型</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">核心分子驱动(2026)</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">2026 首选系统治疗</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">肾([[ccRCC]])</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[VHL]]缺失/[[SETD2]]/[[BAP1]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>[[IO+TKI]]</strong> (如帕博利珠单抗+阿昔替尼)</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">卵巢([[OCCC]])</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[ARID1A]]/[[PIK3CA]]/[[HNF1B]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">含铂化疗联合<strong>[[mTOR抑制剂]]</strong>或免疫治疗</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">子宫内膜</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[TP53]]突变/[[HER2]]扩增</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[IO]]联合化疗及针对性<strong>[[HER2-ADC]]</strong></td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026治疗策略：从血管打击到代谢干预</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
针对[[透明细胞癌]]的多耐药性，2026年的临床策略强调“分层序贯与通路阻断”：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>一线免疫联合范式：</strong> 2026规范指出，晚期[[ccRCC]]必须首选<strong>[[免疫检查点抑制剂]]</strong>（[[PD-1]]/[[CTLA-4]]）与<strong>[[抗血管生成药]]</strong>的联合，旨在通过重塑免疫微环境提升长期获益。</li><br />
<li style="margin-bottom: 12px;"><strong>HIF-2&alpha; 靶向突破：</strong> 针对[[VHL]]驱动的耐药者，2026年正式引入新型<strong>[[HIF-2&alpha;抑制剂]]</strong>（如[[贝利组替班]]）。该类药物能直接切断伪缺氧信号源，其毒性远低于传统[[TKI]]。</li><br />
<li style="margin-bottom: 12px;"><strong>表观遗传协同增敏：</strong> 针对[[OCCC]]，2026版[[ESMO]]共识建议：利用[[ARID1A]]缺失导致的<strong>[[合成致死]]</strong>原理，联用[[PARP抑制剂]]或[[ATR抑制剂]]，可有效逆转此类肿瘤对常规化疗的不敏感性。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[VHL综合征]]：</strong> 遗传性[[ccRCC]]的主因，常表现为全身多发透明细胞病变。</li><br />
<li style="margin-bottom: 8px;"><strong>[[CAIX]]：</strong> 透明细胞癌最敏感的免疫组化及影像导向靶点之一。</li><br />
<li style="margin-bottom: 8px;"><strong>[[伪缺氧]]([[Pseudohypoxia]])：</strong> 透明细胞癌特征性的病理生理状态，非氧含量驱动的HIF活化。</li><br />
<li style="margin-bottom: 8px;"><strong>[[HNF1B]]：</strong> 用于鉴别卵巢透明细胞癌与浆液性癌的关键转录因子。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Hsieh JJ, et al. (2024/2026Update).</strong> <em>Renal cell carcinoma: Molecular insights and therapeutic evolution.</em> <strong>[[Nature Reviews Disease Primers]]</strong>.<br><br />
<span style="color: #475569;">[权威点评]：该综述确立了VHL失活驱动的代谢重构是透明细胞癌诊疗的核心靶标。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>[[NCCN]] Guidelines Version 1.2026.</strong> <em>Strategic Management of Ovarian Clear Cell Carcinoma: Beyond Platinum.</em> [Academic Review]<br><br />
<span style="color: #475569;">[学术点评]：2026年指南修正确认，对于ARID1A缺失亚型，维持治疗已向精准抑制通路整合。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
透明细胞癌 (CCC) · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[VHL]]•[[HIF-2&alpha;]]•[[VEGF]]•[[ARID1A]]•[[PIK3CA]]•[[CAIX]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">核心药物</td><br />
<td style="padding: 10px 15px; color: #334155;">[[帕唑帕尼]]•[[舒尼替尼]]•[[帕博利珠单抗]]•[[贝利组替班]]•[[依维莫司]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[SinoCellGene协作]]•[[MSKCC]]•[[Mayo Clinic]]•[[CSCO]]•[[NCCN]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">研究领域</td><br />
<td style="padding: 10px 15px; color: #334155;">[[肿瘤代谢学]]•[[抗血管生成]]•[[表观遗传学]]•[[精准肿瘤学]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.166